CORXEL to Participate in Upcoming Investor Conferences

BERKELEY HEIGHTS, N.J., Sept. 02, 2026 — Corxel Pharmaceuticals Limited (“CORXEL” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic conditions around the world, today announced the Company will participate in the following upcoming investor conferences:

Wells Fargo 21****st Annual Healthcare Conference

Format:

Company Presentation and 1x1 Meetings

Date and Time:

September 9, 2026, 10:15 a.m. ET

Location:

Boston

Morgan Stanley 24****th Annual Healthcare Conference

Format:

1x1 Meetings

Date and Time:

September 16, 2026

Location:

New York

About CORXEL

CORXEL, a Cayman Islands exempted company, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic conditions around the world. CORXEL is led by an experienced management team that has a strong track record of identifying, in-licensing and developing attractive clinical product candidates directed at validated targets with proven mechanisms of action (MoAs). CORXEL’s diverse portfolio of clinical-stage product candidates has the potential to redefine treatment standards and address key limitations of current therapies for multiple cardiometabolic indications. CORXEL is developing selective small molecule compounds across the cardiometabolic spectrum with the lead product candidate CX11, an oral small molecule GLP-1 RA under clinical development for obesity and overweight conditions and T2DM, JX10, a thrombolytic and anti-inflammatory agent for acute ischemic stroke and CX12, an oral small molecule amylin RA under pre-clinical development. CORXEL also has additional small molecule programs in development targeting validated obesity targets.

For further information about CORXEL, please visit www.corxelbio.com.

Contacts

Corxel Pharmaceuticals

[email protected]

Madelin Hawtin

[email protected]